**Supplementary table S1: additional treatment with avastin stratified by (a) TCGA subtype and (b) EGFR amplification status**

**a**

|  | Classical | Mesenchymal | Proneural | p Value |
|---|---|---|---|---|
|  | n (%) | n (%) | n (%) |  |
| **Number of treatment pre bevacizumab** | | | | |
| 0 | 1 (5%) | 1 (5%) | 0 (0%) | 0.453 |
| 1 | 5 (26%) | 5 (24%) | 5 (22%) |  |
| 2 | 7 (37%) | 9 (43%) | 10 (43%) |  |
| 3 | 4 (21%) | 6 (29%) | 3 (13%) |  |
| 4 | 2 (11%) | 0 (0%) | 5 (22%) |  |
| **Number of treatment during bevacizumab** | | | | |
| 0 | 11 (58%) | 9 (43%) | 9 (39%) | 0.588 |
| 1 | 5 (26%) | 10 (48%) | 10 (43%) |  |
| 2 | 2 (11%) | 2 (10%) | 4 (17%) |  |
| 3 | 1 (5%) | 0 (0%) | 0 (0%) |  |
| **Number of treatment post bevacizumab** | | | | |
| 0 | 10 (53%) | 13 (62%) | 17 (74%) | 0.133 |
| 1 | 5 (26%) | 7 (33%) | 3 (13%) |  |
| 2 | 4 (21%) | 0 (0%) | 1 (4%) |  |
| 3 | 0 (0%) | 1 (5%) | 1 (4%) |  |
| 4 | 0 (0%) | 0 (0%) | 1 (4%) |  |

**b**

| EGFR amplification status | | | | |
|---|---|---|---|---|
| | **No** | **Yes** | **Unknown** | **p value** |
| **Number of treatment pre bevacizumab** | | | | |
| 0 | 0 (0%) | 2 (9%) | 0 (0%) | 0,298 |
| 1 | 8 (30%) | 6 (26%) | 1 (8%) | |
| 2 | 10 (37%) | 7 (30%) | 9 (69%) | |
| 3 | 5 (19%) | 5 (22%) | 3 (23%) | |
| 4 | 4 (15%) | 3 (13%) | 0 (0%) | |
| **Number of treatment during bevacizumab** | | | | |
| 0 | 11 (41%) | 11 (48%) | 7 (54%) | 0,785 |
| 1 | 13 (48%) | 7 (30%) | 5 (38%) | |
| 2 | 3 (11%) | 4 (17%) | 1 (8%) | |
| 3 | 0 (0%) | 1 (4%) | 0 (0%) | |
| **Number of treatment post bevacizumab** | | | | |
| 0 | 20 (74%) | 15 (65%) | 5 (38%) | 0,109 |
| 1 | 5 (19%) | 5 (22%) | 5 (38%) | |
| 2 | 1 (4%) | 3 (13%) | 1 (8%) | |
| 3 | 0 (0%) | 0 (0%) | 2 (15%) | |
| 4 | 1 (4%) | 0 (0%) | 0 (0%) | |